Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Reexamination Certificate
2009-09-10
2011-12-27
Davis, Ruth (Department: 1651)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
C424S422000, C424S572000, C435S325000, C435S371000
Reexamination Certificate
active
08084048
ABSTRACT:
A tissue graft construct for use in repairing diseased or damaged tissues is provided. The tissue graft construct comprises a matrix composition selected from the group consisting of liver basement membrane and extracts and hydrolysates thereof, and processed collagen from vertebrate non-submucosal sources, added endothelial cells, and at least one additional preselected, exogenous population of cells which enhance the initiation of vessel-like structures in the grant. The preselected population of cells can be a population of non-keratinized or keratinized epithelial cells or a population of mesodermally derived cells selected from the group consisting of fibroblasts, smooth muscle cells, skeletal muscle cells, cardiac muscle cells, multi-potential progenitor cells, pericytes, osteogenic cells, and any other suitable cell type, preferably selected based on the tissue to be repaired. Methods for enhancing the vascularization in vivo of these tissue graft constructs and for preparing these graft constructs are also provided.
REFERENCES:
patent: 4829000 (1989-05-01), Kleinman et al.
patent: 4883864 (1989-11-01), Scholz
patent: 4902508 (1990-02-01), Badylak et al.
patent: 4956178 (1990-09-01), Badylak et al.
patent: 5108424 (1992-04-01), Hoffman et al.
patent: 5275826 (1994-01-01), Badylak et al.
patent: 5281422 (1994-01-01), Badylak et al.
patent: 5352463 (1994-10-01), Badylak et al.
patent: 5554389 (1996-09-01), Badylak et al.
patent: 5641518 (1997-06-01), Badylak et al.
patent: 5814328 (1998-09-01), Gunasekaran
patent: 5863531 (1999-01-01), Naughton et al.
patent: 5885619 (1999-03-01), Patel et al.
patent: 5945101 (1999-08-01), Berg et al.
patent: 5955110 (1999-09-01), Patel et al.
patent: 6022743 (2000-02-01), Naughton et al.
patent: 6099567 (2000-08-01), Badylak et al.
patent: 6127143 (2000-10-01), Gunasekaran
patent: 6171344 (2001-01-01), Atala
patent: 6187039 (2001-02-01), Hiles et al.
patent: 6206931 (2001-03-01), Cook et al.
patent: 6241981 (2001-06-01), Cobb et al.
patent: 6264992 (2001-07-01), Voytik-Harbin et al.
patent: 6358284 (2002-03-01), Fearnot et al.
patent: 6375989 (2002-04-01), Badylak et al.
patent: 6379710 (2002-04-01), Badylak
patent: 6419920 (2002-07-01), Mineau-Hanschke et al.
patent: 6475232 (2002-11-01), Babbs et al.
patent: 6485723 (2002-11-01), Badylak et al.
patent: 6918396 (2005-07-01), Badylak et al.
patent: 6962814 (2005-11-01), Mitchell et al.
patent: 7087089 (2006-08-01), Patel et al.
patent: 7175841 (2007-02-01), Badylak et al.
patent: 7771717 (2010-08-01), Badylak et al.
patent: 7776596 (2010-08-01), Badylak
patent: 7795022 (2010-09-01), Badylak
patent: 7815686 (2010-10-01), Badylak
patent: 2003/0113302 (2003-06-01), Revazova et al.
patent: 2005/0202058 (2005-09-01), Hiles et al.
patent: 2006/0257377 (2006-11-01), Atala et al.
patent: 2000-516503 (2000-12-01), None
patent: WO 98/06445 (1998-02-01), None
patent: WO 98/25637 (1998-06-01), None
patent: WO 00/15765 (2000-03-01), None
patent: WO 00/62833 (2000-10-01), None
patent: WO 01/10355 (2001-02-01), None
patent: WO 01/45765 (2001-06-01), None
patent: WO 01/48153 (2001-07-01), None
patent: WO 01/78754 (2001-10-01), None
patent: WO 02/07646 (2002-01-01), None
patent: WO 02/14480 (2002-02-01), None
patent: WO 02/20729 (2002-03-01), None
Nugent et al., “Endothelial Implants Inhibit Intimal Hyperplasia After Porcine Angioplasty,”Circulation Research, Mar. 5, 1999, vol. 84, No. 4, p. 384-391.
Voytik-Harbin et al., “Three-Dimensional Imaging of Extracellular Matrix and Extracellular Matrix-Cell Interactions,” Methods in Cell Biology, Ch. 27, vol. 43, pp. 583-597.
Brightman et al., “Time-Lapse Confocal Reflection Microscopy of Collagen Fibrillogenesis and Extracellular Matrix Assembly In Vitro,”Biopolymers, vol. 54, 2000, pp. 222-234.
Asem et al., “Basal Lamina of Avian Ovarian Follicle: Influence on Morphology of Granulosa Cells In-Vitro,”Comparative Biochemistry and Physiology, Part C, 125 (2000), pp. 189-201.
Asem et al., “Effect of Basal Lamina on Progesterone Production by Chicken Granulosa Cells In Vitro—Influence of Follicular Development,”Comparative Biochemistry and Physiology, Part C, 125 (2000), pp. 233-244.
Hirschi et al., “PDGF TGF-β, and Heterotypic Cell-Cell Interactions Mediate Endothelial Cell-Induced Recruitment of 10T1/2 Cells and Their Differentiation to a Smooth Muscle Fate.”The Journal of Cell Biology, vol. 141, No. 3, May 4, 1998, pp. 805-814.
Campbell et al., “Endothelial Cell Influences on Vascular Smooth Muscle Phenotype.”Ann. Rev. Physiol., 1986, vol. 48, pp. 295-306.
Badylak et al., “Endothelial cell adherence to small intestinal submucosa: an acellular bioscaffold,”Biomaterials, vol. 20, 1999, pp. 2257-2263.
Castano. E., et al., “Inhibition of DNA Synthesis by Aspirin in Swiss 3T3 Fibroblasts,” Journal of Pharmacology and Experimental Therapeutics. vol. 280, No. 1, 1997, pp. 366-372.
Bhatia, S. N., et al., “Controlling Cell Interactions by Micropatterning in Co-Cultures: Hepatocytes and 3T3 Fibroblasts,” Journal of Biomedical Materials Research, vol. 34, 1997, pp. 189-199.
Liu, C. H., et al., “Effects of Salvianolic Acid-A on NIH/3T3 Fibroblast Proliferation. Collagen Synthesis and Gene Expression,” World J. Gastroentero, vol. 6, No. 3. 2000, pp. 361-364.
Keyes. K,. et al., “An In Vitro Tumor Model: Analysis of Angiogenic Factor Expression after Chemotherapy,” Cancer Research, vol. 62, 2002, pp. 5597-5602.
Montesano, R., “Paracrine Induction of Angiogenesis in Vitro by Swiss 3T3 Fibroblasts” Journal of Cell Science, vol. 105, 1993, pp. 1013-1024.
Nerem, R., “Tissue Engineering: The Hope, The Hype and The Future” Tissue Engineering, vol. 12, No. 5, 2006, p. 1143-1150.
“Artificial Blood Vessel”, English translation of Japanese Patent Application Publication No. 3-12169, 1991, 16 pages.
“In Vivo Plant Material”. English translation of Japanese Patent Application Publication No. 1-170466, 1989, 13 pages.
Ho. M., et al.. “Identification of Engothelial Cell Genes by Combined Database Mining and Microarray Analysis”, Physiol Genomics, vol. 13, 2003, pp. 249-262.
Maru, Y. et al., “An Oncogenic Form of the Flt-1 Kinase has a Tubulogenic Potential in a Sinusoidal Endothelial Cell Line,” European Journal of Cell Biology, vol. 79, 2000, pp. 130-143.
Russmann H. et al., “Translocation ofYersinia enterocoliticathrough an Endothelial Monolayer by Polymorphonuclear Leukocytes,” Infection and Immunity, vol. 64, No. 3, 1996, pp. 1016-1019.
Kubota Y. et al., “Role of Laminin and Basement Membrane in the Morphological Differentiation of Human Endothelial Cells into Capillary-like Structures,” Journal of Cell Biology, vol. 107, 1988, pp. 1589-1598.
Block, S., “Peroxygen Compounds,” Disinfection, Sterilization and Preservation, 4th Edition 1991, pp. 167-181. Philadelphia, Lea & Febiger.
Denton. G.W., “Chlorhexidine,” Disinfection, Sterilization and Preservation, S.Block, editor, 4th Edition 1991, pp. 274-289. Philadelphia, Lea & Febiger.
Yang et al., “Tissue engineered artificial skin composed of dermis and epidermis,” Artificial Organ, 2000; 24(1):7-17.
Lim et al., “Microencapsulated Islets as Bioartificial Endocrine Pancreas,” Science, 1980, 210(4472):908-10.
U.S. Appl. No. 12/852,897, filed Aug. 9, 2010, Badylak et al.
Barnes & Thornburg LLP
Davis Ruth
Purdue Research Foundation
LandOfFree
Vascularization enhanced graft constructs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vascularization enhanced graft constructs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vascularization enhanced graft constructs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4255257